ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Simultaneous Nucleation-Nanowelding Generates Uniform Plasmonic Au-Au Nanojunctions in 3D-Welded Gold Nanostructures.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A previously unexplored controllable one-pot kinetically controlled growth-coupled nanowelding strategy was introduced for engineering uniform plasmonic Au-Au nanojunctions in size-matched 3D-welded nanostructures, where nanojunctions are formed intrinsically during nanoparticle growth instead of traditional postwelding. The structural and physicochemical properties of the nanostructures were comprehensively characterized. Time-dependent structural characterization and spectroscopic analyses supported the growth-coupled nanowelding and revealed a relationship between nanojunctions and reproducible SERS performances of welded golds (intra-month-%RSD = 8.5%). The welded-golds exhibited an SERS enhancement factor, EF, of 2.26 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.